Financial Performance - The company achieved operating revenue of 1 billion yuan in 2024, a year-on-year increase of 19.38% [2] - The net profit attributable to the parent company reached 0.48 billion yuan, growing by 14.00% year-on-year [2] - Basic earnings per share increased to 0.63 yuan, reflecting a growth of 50.00% [2] Revenue Composition - The revenue from thiocyanate erythromycin accounted for 32.35% of total revenue [2] - Cephalosporin intermediates contributed 24.96% to the main business revenue [2] - Penicillin intermediates made up 41.95% of the main business revenue [2] - Other products represented 0.74% of the main business revenue [2] Key Growth Drivers - Increased sales volume and prices of cephalosporin products contributed to the rise in net profit [3] - Continuous improvement in technology reduced production costs, leading to higher net profit [3] - A decrease in interest expenses due to reduced interest-bearing debt also supported profit growth [3] Market Outlook - The price of thiocyanate erythromycin is expected to maintain a steady upward trend [4] - Cephalosporin product prices are stabilizing after a recovery in 2024, with minor fluctuations anticipated [4] - Penicillin products faced price pressure but are expected to stabilize at current levels [4] Cost Management - The company improved production technology, increasing the yield of thiocyanate erythromycin by 5% [8] - The introduction of high-yield strains in the cephalosporin production line improved extraction rates by 3.5% [8] - Overall production costs are expected to decrease further through process optimization and multi-product production lines [8] Financial Ratios - The overall gross margin for 2024 was 36.39%, an increase of 4.82% year-on-year [9] - Financial expense ratio decreased to 0.84%, down by 0.22% year-on-year [11] Future Projections - The company anticipates stable revenue levels in the antibiotic intermediate sector for 2025, with potential profit improvements from ongoing cost reductions [9] - The synthetic biology segment aims for over 100 million yuan in revenue and a significant profit contribution [9] Strategic Initiatives - The company plans to enhance its synthetic biology capabilities, focusing on high-value products and expanding its product matrix [7] - AI technology is being integrated into production processes to optimize fermentation and improve yield [11] - The company is exploring new markets and product lines, particularly in Kazakhstan, focusing on mature bulk products [14] Risk Factors - Potential impacts from macroeconomic fluctuations, such as inflation and geopolitical tensions, could affect product demand [21] - Raw material price volatility poses a risk to profit margins, influenced by market demand and climate conditions [21]

Core Viewpoint - The company Chuaning Biological has reported significant growth in revenue and net profit, driven by increased sales and prices of its main products, as well as improvements in manufacturing processes through AI technology [1][2][3] Financial Performance - In 2024, Chuaning Biological achieved a revenue of 5.758 billion yuan, a year-on-year increase of 19.38%, and a net profit of 1.4 billion yuan, up 48.88%, both reaching historical highs [1] - The company's revenue from pharmaceutical intermediates was 5.356 billion yuan, an increase of over 900 million yuan from the previous year, with a year-on-year growth rate exceeding 20% [1] - The gross profit margin for the pharmaceutical intermediates business improved by 5.42 percentage points to 38.63% [1] Product and Market Insights - Chuaning Biological specializes in the research and sales of antibiotic intermediates, including three main categories: thiocyanate erythromycin, cephalosporin intermediates, and penicillin derivatives [1] - The revenue contribution from the three main products to total revenue was 32.35%, 24.96%, and 41.95%, respectively [1] AI and Technological Advancements - The company has begun utilizing AI to enhance manufacturing processes, achieving dynamic control in the production line of thiocyanate erythromycin, which has led to increased fermentation yields and reduced production fluctuations [2] - Chuaning Biological plans to continue leveraging AI and synthetic biology technologies to further stabilize production fluctuations and improve extraction yields by 2025 [3] Strategic Investments - In February of the previous year, Chuaning Biological acquired a 16.67% stake in Shanghai Jinchang Technology, which focuses on AI applications in biotechnology [2]

Group 1 - The company raised a total of RMB 1,114 million through the issuance of 222,800,000 shares at a price of RMB 5.00 per share, with a net amount of RMB 1,021.68 million after deducting expenses [2][5][16] - As of December 31, 2024, the company has invested a total of RMB 910.22 million from the raised funds, with specific allocations including RMB 188.54 million for the Shanghai Research Institute project and RMB 196.68 million for the Green Circular Industry Park project [5][16] - The company has established special accounts for the management of raised funds, ensuring compliance with regulatory requirements and protecting investor interests [6][7] Group 2 - The company has adjusted the implementation method of the Shanghai Research Institute project from leasing to purchasing, increasing the investment amount from RMB 200 million to RMB 300 million, with an additional RMB 100 million sourced from over-raised funds [12][13] - The company reported no idle raised funds used for temporary working capital during the reporting period [10] - The company has confirmed that the disclosure of the use of raised funds aligns with actual usage, with no violations reported [13][14] Group 3 - The company plans to distribute a cash dividend of RMB 2.70 per 10 shares, totaling RMB 601.33 million, which represents 42.94% of the net profit attributable to shareholders for the year 2024 [48][49] - The profit distribution plan has been approved by the board and will be submitted for shareholder approval [50][51] - The company will not conduct a capital reserve transfer to increase share capital in 2024 [49]

Core Viewpoint - Chuaning Bio reported a positive overall business performance for the fiscal year 2024, with significant growth in revenue and net profit, driven by increased sales and improved production efficiency [1][2] Financial Performance - The company achieved an operating income of 5.758 billion yuan, representing a year-on-year increase of 19.38% [1] - Net profit attributable to shareholders reached 1.4 billion yuan, up 48.88% year-on-year [1] - Basic earnings per share were 0.63 yuan, reflecting a growth of 50.00% compared to the previous year [1] Business Segments - The main business revenue breakdown includes: - Erythromycin thiocyanate: 32.35% - Cephalosporin intermediates: 24.96% - Penicillin intermediates: 41.95% - Other products: 0.74% [1] Strategic Development - The company adheres to a "dual-drive" strategy focusing on "biological fermentation" and "synthetic biology" [1][2] - Chuaning Bio has become a leading enterprise in the global biological fermentation technology industry, maintaining stable growth in product orders and prices [2] Investment and Innovation - The company invested 60 million yuan in a private equity fund to enhance its competitive edge and resource allocation [2] - A strategic partnership with Shanghai Jinchang Technology was established to integrate AI into fermentation and synthetic biology research, aiming to improve production efficiency and reduce costs [3] Future Outlook - Chuaning Bio plans to continue its "dual-drive" strategy, leveraging AI technology to maintain its leading position in the biological fermentation sector [4] - The company announced a profit distribution plan, proposing a cash dividend of 2.70 yuan per 10 shares, with total dividends since listing amounting to 1.3 billion yuan [4]

一直在路上，所以停下脚步，只在于分享 包括： 新 材料/ 半导体 / 新能源/光伏/显示材料 等 添加 小编微信 ，遇见 志同道合 的你 写在前面 （文末有惊喜） 正文 = 在 1 is fo 基础化工 点击 最 下方 "在看"和" "并分享，"关注"材料汇 行业专题 以生物造万物. 构建 Al+新质生产力新业态 合成生物深度系列报告之一 主要观点: ● 合成生物学是生产力转型升级新方向 合成生物学是一门基于工程化的设计理念,结合生物学、化学、医 学、农学、工程学、计算机与数据科学等交叉学科技术,旨在设计 和构建新的生物系统,以实现特定的功能,其本质是让细胞为人类 工作生产想要的物质。合成生物学和发酵工程的区别在于是否对细 胞进行定向性干预,大幅提升微生物细胞工厂效率。目前合成生物 学可合成的大宗化学品仅几十种,在整体基础化学品中的占比还非 常有限,还无法颠覆性替代传统化工,但在部分领域有比较好的应 用场景,具有战略与商业角度的优势,生物制造未来提升空间巨 大。 ● Al 赋能上游+政策推动落地,合成生物学东风将至 当前,国际合成生物学优势力量主要分布在美、欧等地,其政策对 我国来说具备一定参考意义,国内也正 ...

伊犁川宁生物技术股份有限公司 2024 年度董事会工作报告 2024 年度，伊犁川宁生物技术股份有限公司（以下简称"公司"）董事会严 格遵守《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《深圳证券交易所创业板股票上市 规则》等有关法律法规、规范性文件及《公司章程》等公司制度的规定，认真履 行股东大会赋予的职责。现将公司董事会 2024 年度工作情况汇报如下： 一、2024 年度公司总体经营情况 2024 年，是我国全面贯彻落实党的二十大精神、深入推进中国式现代化建 设的关键之年，也是公司紧跟国家战略布局、迈向高质量发展的重要一年。随着 全球抗生素需求增长，在抗生素中间体行业稳步发展的态势下，公司紧跟国家高 质量发展的战略目标，助力开辟生物制造战略性新兴产业的新赛道。这一年，公 司全面开启了高质量发展的新征程，以创新驱动为核心，全力推动产业升级，实 现了业绩的显著增长。同时，公司在产品研发、技术创新、团队建设以及降本增 效等方面均取得了丰硕成果，为未来的持续发展奠定了坚实基础。 报告期内，公司实现营业总收入 575,830.77 万元，比上年同期增长 ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-020 伊犁川宁生物技术股份有限公司 关于变更公司会计政策的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（以下简称"公司"）根据中华人民共和国 财政部（以下简称"财政部"）颁布的《企业会计准则解释第 17 号》（财会〔2023〕 21 号，以下简称"准则解释 17 号"）《企业会计准则解释第 18 号》（财会〔2024〕 24 号，以下简称"准则解释 18 号"）相关要求，变更有关会计政策。本次会计 政策变更是公司根据法律法规和国家统一的会计制度的要求进行的变更，根据 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等相关规定，无需提交公司董事会或股东大会审议。相关会计政策变更的具体情 况如下： 一、本次会计政策变更概述 （一）变更的原因及依据 2023 年 10 月 25 日，财政部发布了《企业会计准则解释第 17 号》（财会 〔2023〕21 号），规定了"关于流动负债与非流动负债的划分""关于供应商融 资安排的披露""关于售后 ...

伊犁川宁生物技术股份有限公司 董事会审计委员会关于2024年度会计师事务所 履行监督职责情况的报告 根据《公司法》《上市公司治理准则》《国有企业、上市公司选聘会计师事 务所管理办法》《深圳证券交易所上市公司自律监管指引第2号——创业板上市 公司规范运作》和《公司章程》等规定和要求，公司董事审计委员会本着勤勉尽 责的原则，恪尽职守，认真履职，对公司2024年度审计机构——天健会计师事务 所（特殊普通合伙）（以下简称"天健会计师事务所"）的履职情况进行监督， 现将董事会审计委员会对会计师事务所履行监督职责的情况汇报如下： 一、会计师事务所基本情况 3、2025年3月31日，公司通过现场结合通讯方式召开了2024年度审计工作事 中沟通会议，公司审计委员会、天健会计师事务所、财务部及董事会办公室工作 人员参加了会议。会议中天健会计师事务所对2024年度审计进度进行了汇报，就 审计过程中发现的问题、审计内容相关调整事项及审计报告的出具情况等进行了 充分沟通，并对审计工作发表意见。 4、2025年4月18日，公司召开董事会第二届审计委员会第十次会议，审议通 过公司2024年年度报告、财务决算、内部控制评价报告等议案，对财 ...

伊犁川宁生物技术股份有限公司 2024 年度内部控制自我评价报告 伊犁川宁生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合伊犁川宁生物技术股份有限公司（以 下简称："本公司"或"公司"）内部控制制度和评价办法，在内部控制日常监督 和专项监督的基础上，我们对公司 2024 年 12 月 31 日（内部控制评价报告基准 日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立 和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公司 董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记 载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营合法合规、资产安全、财务报告及相关 信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在固 有局限性，故仅能为实现上述目标提供合理保证。此外，由 ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-008 伊犁川宁生物技术股份有限公司 关于续聘公司2025年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天健会计师事务所（特殊普通合伙）（以下简称"天健会计师事务所"）在 担任伊犁川宁生物技术股份有限公司（以下简称"公司"）2024 年度审计机构 期间，能够遵循独立、客观、公正的执业准则，恪尽职守，顺利完成了公司 2024 年度财务报告的审计工作，较好地履行了聘约所规定的责任与义务。 鉴于天健会计师事务所具备证券、期货相关业务审计从业资格，为公司提供 审计服务过程中能够遵循独立、客观、公允、公正的执业准则，对公司资产状况、 经营成果所做审计实事求是，所出审计报告客观、真实，同时已与公司建立良好 的业务合作关系，为保持公司审计工作的连续性和稳定性，公司于 2025 年 4 月 18 日召开第二届董事会第九次会议，审议通过了《关于续聘公司 2025 年度审计 机构的议案》，公司董事会同意续聘天健会计师事务所为公司 2025 年度审计机 构，聘任期限为一年。本次拟续聘会计师事务所事 ...